News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Carboat post# 272529

Wednesday, 09/14/2016 1:39:46 PM

Wednesday, September 14, 2016 1:39:46 PM

Post# of 347009
Your opinion is totally flawed, beginning with Avid. Avid is about to do things no other small biotech has accomplished and at that time it is when most will realize that without Avid there is no Peregrine and without Pererine there is no Avid.

The days where it was cost effective for a small biotech to outsource manufacturing is not over.....because that is what must happen MOST times for a normal situation and a hopeful drug to bring to market.

Peregrine is not, though... the average small biotech, and I think you are well aware of this.

Paradigm shifts about to make a new fault line right in the middle of Big Pharma and depending on which side one is on will mean the difference of remaining competitive in IO combo treatments or falling behind and never able to regroup.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y